Actively Recruiting
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
Led by Chinese PLA General Hospital · Updated on 2025-08-14
750
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, blood biomarker testing, genotyping, and cognitive assessments to identify early imaging biomarkers and construct models of disease progression.
CONDITIONS
Official Title
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 55-90 years (inclusive).
- Willing and able to participate in baseline assessment and longitudinal follow-up; voluntary provision of biospecimens and personal information, and commitment to complete all follow-up visits.
- Able to undergo MRI scanning (no contraindications to MRI).
- For cognitively normal (CN) group: No memory complaints beyond age expectations, MMSE score 26-30 (exceptions allowed with less education), CDR = 0, normal cognitive and daily functioning.
- For mild cognitive impairment (MCI) group: Subject, partner, or physician reports memory concerns; MMSE 26-30 (same as CN); CDR = 0.5; general cognition and function relatively preserved; does not meet Alzheimer's disease criteria.
- For Alzheimer's disease (AD) group: Subject, partner, or physician reports memory concerns; MMSE score below 26 (exceptions allowed); CDR = 0.5 or 1.0; meets standard probable AD diagnostic criteria or 2024 NIA-AA criteria.
You will not qualify if you...
- Major neurological diseases other than Alzheimer's disease such as stroke, congenital intellectual disability, intracranial tumors, epilepsy, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, severe head trauma with lasting deficits.
- Severe psychiatric disorders requiring medication control or other known brain structural abnormalities.
- Significant organ failure (heart, liver, kidney), malignant tumors, or short life expectancy making follow-up unlikely.
- Contraindications to MRI including claustrophobia, incompatible pacemaker, aneurysm clip, artificial heart valve, cochlear implant, or other metallic implants.
- Other clinical history or examination findings deemed unsafe for MRI or follow-up by investigators.
- Use of investigational drugs within one month before enrollment or during the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here